One classical feature of cancer cells is their metabolic acquisition of a highly glycolytic phenotype. Carbon monoxide (CO), one of the products of the cytoprotective molecule heme oxygenase-1 (HO-1) in cancer cells, has been implicated in carcinogenesis and therapeutic resistance. However, the functional contributions of CO and HO-1 to these processes are poorly defined. In human prostate cancers, we found that HO-1 was nuclear localized in malignant cells, with low enzymatic activity in moderately differentiated tumors correlating with relatively worse clinical outcomes. Exposure to CO sensitized prostate cancer cells but not normal cells to chemotherapy, with growth arrest and apoptosis induced in vivo in part through mitotic catastrophe. CO targeted mitochondria activity in cancer cells as evidenced by higher oxygen consumption, free radical generation and mitochondrial collapse. Collectively, our findings indicated that CO transiently induces an anti-Warburg effect by rapidly fueling cancer cell bioenergetics, ultimately resulting in metabolic exhaustion.
Introduction
Epithelial cancers, including prostate, breast and lung cancer are still leading causes of deaths in the US and treatment for advanced disease is limited(1). A standard of first-line care for advanced and metastatic cancers remains chemotherapy such as taxols, doxorubicin and cisplatin (2) . Rapid proliferation of primary tumor and cancer cell survival during spread to distant organs as well as resistance to treatment are possible in part due to the remarkable metabolic adaptation known as the Warburg effect(3). The Warburg effect is characterized by increased glucose uptake and elevated glycolysis with a limited oxygen consumption rate (OCR) resulting in lactic acid fermentation (4) . High rates of energy consuming processes including protein, DNA and fatty acid synthesis in cancer cells is often accompanied by an increased oxidative state of dysfunctional mitochondria (5) . The promotion of tumor growth requires in part, a selection of cancer cells with repressed mitochondrial activity and biogenesis (6) . Defects in mitochondrial ROS metabolism from electron transport chains in cancer cells have been linked directly to increased cancer cell glucose metabolism. The free radical theory of cancer implicates ROS as a principal cause of early mutations as well as being involved in the response to treatment (7) (8) (9) (10) (11) .
Heme oxygenases (HO) which degrade heme to biliverdin, carbon monoxide (CO) and iron are critical modulators of metabolism and mitochondrial activity.
,, Expression of HO-1, the stress inducible isoform, is strictly regulated while HO-2 is ubiquitously expressed primarily in brain and testes. Their functional role in cancer has not been clearly elucidated and remains controversial. HO-1 can impart potent anti-proliferative and proapoptotic effects via antioxidant mechanisms as demonstrated in breast and lung cancer cell lines. (12, 13) Better survival rates were observed in colorectal cancer patients where HO-1 expression correlated with lower rates of lymphatic tumor invasion. In contrast, overexpression of HO-1 has been shown to accelerate pancreatic cancer aggressiveness by increasing tumor growth, angiogenesis and metastasis (14) .
Similar effects were observed in melanoma (15) , gastric (16) and renal cancers (17) . In prostate cancer patients, HO-1 is localized in the nucleus and correlated with cancer progression (18) .
Nuclear HO-1 was also detected in head and neck squamous carcinomas and associated with tumor progression (19) . Recently, nuclear HO-1 has been linked to resistance to Imatinib in chronic myeloid leukemia (20) . Further evidence for HO-1 in cancer incidence presides in the identification of a GT length polymorphism of the HO-1 promoter that is highly correlative with cancer severity (21) . Individuals with long GT repeats in the HO-1 promoter and associated low expression of HO-1 showed a higher frequency of gastric or lung adenocarcinoma and oral squamous cancer versus those with short GT repeats and higher HO-1 expression (22) . CO, biliverdin, bilirubin as well as iron and ferritin serve as potential modulators of tumorigenesis however all have been minimally studied in cancer (23) , .
In the present studies, we first performed a detailed analysis of a large cohort of prostate cancer patients and confirmed HO-1 nuclear localization in moderately advanced tumors where it is enzymatically inactive and therefore may be a critical regulator of cancer progression. We tested the hypothesis that HO-1, through its ability to generate CO, modulates cancer cell growth in vitro and in vivo using human and murine prostate and lung cancer models.
Paradoxically, CO rapidly enhanced mitochondria activity of cancer cells that results in metabolic exhaustion and cellular collapse causing tumor regression. Further, CO increased cancer cell sensitivity to chemotherapeutics one thousand fold while simultaneously protecting normal cell growth and viability.
Materials and Methods

PCa samples & Tissue microarray
Benign and malignant samples of 482 patients undergoing radical prostatectomy for localized PCa were subjected in duplicate to tissue microarray (TMA) constructs of 1.0 mm in diameter and scored for immunohistochemical staining intensity as previously described (24) . The majority of samples were successfully prepared (~95%) and Gleason grades were evaluated by a 
Immunohistochemistry
Immunohistochemical staining of paraffin embedded sections from human TMA blocks was performed as previously described (25) . Mouse antibody against HO-1 (Stressgen, #OSA-110) was used at 1:200 dilution. Secondary antibody was used as a negative control.
Immunohistochemistry, immunofluorescence and immunostaining on the cell lines and mouse tumor samples were performed as previously described 37 . Briefly, formalin-fixed or Zn-fixed paraffin embedded tumor tissues were processed for antigen retrieval with high pressurecooking in citrate buffer for 1 hour. Tissues sections were then blocked with 7% horse serum for 30 min, followed by incubation with primary antibody overnight. Biotin-labeled secondary antibody (Vector Laboratories) was applied for 1h at RT followed by Vectastain Elite ABC Kit and detection with ImmPact DAB (Vector Laboratories). Immunofluorescence staining was performed on frozen tumor sections or cultured cells on glass cover slips. Tissues or cells were fixed with 2% paraformaldehyde for 10 min followed by permeabilization with 0.05% Triton X-6 100. After blocking with 7% horse serum, sections were probed with primary antibody and secondary fluorescently labeled antibody (Molecular Probes). Hoechst-33258 (Molecular Probes, Invitrogen) was used to stain the nuclei.
The following antibodies were applied: polyclonal rabbit anti-HO-1 (Stressgen) was used at 1:1000. Prohibitin antibody was purchased from Epitomics Inc. (Burlingame, CA).
Cytochrome C antibody was obtained from Cell Signaling (Beverly, MA). mtTFA and vimentin antibodies were purchased from Santa Cruz Biotechnology. Anti-mouse Ki67 antibody was from Dako. Anti-mouse Thy-1, CD31, antibody was from BD Biosciences, Pharmingen and anti-P (Ser10)-Histone H3 were from Cell Signaling. TUNEL staining was performed using
ApopTag Peroxidase in situ apoptosis detection Kit (Chemicon, Millipore, Billerica, MA) following manufacturer's protocol.
Animal tumor models
The tumor models were approved by the BIDMC IACUC. Nu/nu mice were purchased from Taconic (Hudson, NY) at 7 weeks of age. Mice were provided food and water ad libitum as needed. After 1-week acclimatization, 1x10 6 PC3 cells were injected into the right flank of mice. Tumors were established for 2 weeks at which point treatment with CO±doxorubicin was begun. Mice were exposed to CO (250ppm, 1 hr/day) as previously described (26 FBS and antibiotics. Cells were treated with camptothecin (0.001μg/ml-10 μg /ml, Sigma) or doxorubicin (10 μg/ml, Sigma) and vehicle control (DMSO) for 1-24 hours. Co-treatment with CO (250 ppm) was performed as previously described (26) . Pegylated catalase (3000 U/ml) and SOD (10 U/ml) were from Sigma and were used 1h prior to CO treatment. Transient transfection PC3 cells were transfected using Amaxa nucleofection or Lipofectamine 2000 as previously described (24) . pCMV control vector or human HO-1 cDNA encoding vector were used for transfection. Transfection efficiency was between 40-50% as estimated with overexpression of GFP by fluorescence microscopy.
Comet assay
PC3 cells were treated with CO or Air for 24h and harvested for COMET SCGE Assay (Assay Designs). The manufacturer's protocol was followed. Cells were viewed by Zeiss Axiovert Apotome Fluorescent microscope at 40x. At least 100 cells were counted and the amount of comets was calculated and expressed per 100 cells. 
HO-1 activity and CO levels in the tissues
PC3 cells were treated with 10 μg/ml doxorubicin or camptothecin for 4 hours and nuclear/cytoplasmic fractions were isolated. HO-1 activity was measured as previously described (27) . We assume that only HO-1 was contributing to the changes in HO activity assay as HO-2 remained unchanged in response to doxorubicin and camptothecin treatment for 4 hours (data not shown). Measurements of CO concentrations were performed on tissue sections as described by Verma et al. (28) . Tumor and normal tissues were harvested immediately after the last exposure of mice to CO and tissues were processed for gas chromatography as described. Briefly, CO was liberated as a gas in a sealed glass vial by adding 25ȝl of water and 5 ȝl of sulfosalicylic acid (SSA; 30% [wt/vol]) to 30 ȝl of diluted tissue homogenate. The vials were incubated on ice for 10 min before being analyzed. The gas in the headspace of the vials was then analyzed quantitatively with a gas chromatograph (GC) equipped with a reducingcompound photometry (RCP) detector (Peak Laboratories, Mountain View, CA), which allowed the CO in gas to be quantified to concentrations as low as 1 to 2 parts per billion (ppb). The amount of CO was then calculated using a calibration curve prepared from CO standards. 
RNA isolation and real time PCR
Total RNA was isolated from PC3 cells after treatment with 10 μg/ml camptothecin with or without CO for 6 or 24 hours using RNeasy Kit (Qiagen, Inc). 2 μg of RNA was used for cDNA synthesis (Invitrogen, Carlsbad, CA). The region of Gadd45α was amplified with specific primers:
The following primers to β-actin were used: F-5'CGCGAGAGAAGATGACCCAGATC3'; R-5'TCACCGGAGTCCATCACGA3'. Real time PCR reactions were performed using 1xSYBR Green PCR Master Mix (BioRad). Primers for MMP2, urokinase plasminogen activator (uPA), VEGF were previously described (24) .
Apoptosis, viability and clonogenic assays
PC3 cells were seeded at 1x10 5 concentration in 6 well plates 24 hours before experiment. Cells were treated with camptothecin (0.001-10 μg/ml) or doxorubicin (10 μg/ml) with CO/Air for 24 hours. Cells were harvested and apoptosis rate was measured using Annexin V-FITC staining according to the manufacturer's protocol (BD Biosciences, San Jose, CA). To test cell viability, PC3 cells were stained with Crystal Violet solution (Sigma-Aldrich) for 10 minutes, followed by extensive wash with double-distilled water. Cells were dried and dissolved in 10% acetic acid, followed by measurement of absorbance at 560 nm on the ELISA reader.
Clonogenic assay: cells were treated in the presence or absence of CO ± chemotherapeutics as above for 24h. After 24h cells were trypsinized and seeded as a subculture with dilution of 1:10-1:100. Colony counts were performed 2 weeks after seeding.
Cell Fractionation
Nuclear and cytoplasmic fraction of PC3 cells were performed using the subcellular fractionation Kit following the manufacturer's protocol (Pierce, Rockford, IL) or BioVision Nuclear/Cytoplasmic Kit extraction (BioVision). Briefly, cells were treated as described above, washed twice with PBS and trypsinized. Pellets were collected and resuspended in ice-cold Cytoplasmic Extraction Reagent (CERI) buffer and vortexed. Lysates were incubated on ice for 10 min and Cytoplasmic Extraction Reagent II (CERII) buffer was added and lysates were incubated for additional 1min on ice. After vortexing, lysates were centrifuge at 16,000 x g and supernatants were collected for the cytoplasmic fraction. Pellets were resuspended in ice-cold Nuclear Extraction Reagent (NER) buffer and incubated on ice for 30 min. Nuclear and cytoplasmic fractions were analyzed by immunoblotting as described above.
Mitochondrial activity and metabolic profiling
SPECT: We used technetium-99m methoxyisobutyl isonitrile ( 
Seahorse Experiments
Cells were seeded in 24 well plate (3x10 4 ) 24 h prior experiment and treated with CO (250 ppm) or Air for 30 minutes or CO was bubbled into the medium and transferred to the reader immediately prior measurment. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured over time.
LDH and glucose measurments
PC3 cells were treated for 6 hours with CO (250 ppm) and harvested in the manufacturer's lysis buffers to measure glucose or lactate (Biovision, Glucose or Lactate Kits)
and process for colorimetric analysis of metabolites. 
MitoTracker Red
CMCRos was purchased from Invitrogen, Molecular Probes and was used at 0.2 μM concentration. Cells were treated for 3.5 hours with Doxorubicin (10 ng/ml) ± CO and MitroTracker Red CMCRos was added for the last 30 min of treatment. Cells were washed and fixed with 2% PFA followed by staining with Hoechst.
Statistical analyses
Statistical analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL).
The differences in the expression of different markers between benign and cancer specimens were evaluated by paired Wilcoxon's rank sum test or Kruskal-Wallis test. Distributions of overall survival and disease-free survival were estimated by the method of Kaplan-Meier, with 95% confidence intervals. Differences between survival curves were calculated using the log- 
Results
Nuclear HO-1 with low activity in prostate cancer correlates with poorer prognosis.
HO-1 has been shown to be expressed and function in the nucleus as a regulator of oxidative stress response transcription factor at the expense, however, of losing enzymatic activity (29) . Based on these data, we hypothesized that nuclear translocation of HO-1 influences the response of cancer cells to therapy. We evaluated 482 tumor specimens from patients with prostate cancer with corresponding benign tissues by tissue microarray to assess the correlation between nuclear HO-1 expression and clinical tumor characteristics. The majority of benign samples showed low overall expression of HO-1 (Fig 1A-B and Supplementary Fig1A ). In contrast, Gleason grade 3 specimens showed significantly higher expression of HO-1 in the nucleus than that of corresponding benign tissue (Fig 1C-D, p=0 .047*). The intensity of nuclear HO-1 staining declined in Gleason grade 4-5 specimens as compare to Gleason grade 3, but did not achieve statistical significance (Fig 1A-H) . Finally, there was no significant difference in cytoplasmic staining of HO-1 in prostate cancer versus adjacent benign samples (data not shown). We reasoned that high nuclear HO-1 expression in moderately differentiated tumors may correspond to the level of oxidative stress or hypoxia that drives progression of differentiated tumors to more advanced disease.
We next evaluated the clinical significance of nuclear HO-1 expression by correlating HO-1 staining with biochemical recurrence (BCR) of PCa as measured by prostate-specific antigen in the circulation(30) as well as overall patient survival (Fig 1H) . High nuclear HO-1 (arbitrary intensity= 3) expression in the cancer biopsies in comparison to low (arbitrary intensity =1) nuclear HO-1 predicts a shorter time to BCR (Fig 1F, p=0. Author Manuscript Published OnlineFirst on October 11, 2013; DOI: 10.1158/0008-5472.CAN- comparison to patients with low nuclear HO-1 (p=0.046) indicating a shorter time to recurrent disease in PCa patients with a lack of enzymatically active nuclear HO-1.
HO-1 Activity and CO Influence the Cancer Cell Response to Genotoxins
Nuclear localized HO-1 is a hallmark of cancer progression in PCa (18) . Comparing the HO-1 localization profiles and activity of non-cancerous cells (epithelial cells and fibroblasts) to cancerous cells (PC3, A549, HepG2, T47D, MDA-468, HeLa) we found that cancer cell lines showed high nuclear expression and low cytoplasmic expression while non-cancerous cells showed high cytosolic expression and low nuclear expression (Fig 2A-B) . We show that when HO-1 is localized to the nucleus it loses its activity in response to common chemotherapeutics (Fig 2C and HO-1 expression in normal cells is required for appropriate DNA repair in response to chemotherapy or irradiation (31) . Using camptothecin and doxorubicin to induce DNA damage, we tested the role of HO-1 and CO on cancer and normal cell death. We observed significant cell death with camptothecin or doxorubicin in vector control-treated PC3 cells as expected.
Overexpression of HO-1 induced further death of PC3 cells in response to camptothecin or doxorubicin (Fig 2D) . A similar effect was observed in cells after exposure to a low concentration of CO (Fig 2 and Supplementary Fig 1B-C) .(32) Dose escalation experiments to induce cell death with camptothecin showed that in the presence of CO, the sensitivity of cells to camptothecin increased synergistically to approximately 1000 fold over chemotherapy-alonetreated cells (Fig 2E and Supplementary Figure 1B-C) . The effect was specific to DNA 
damage inducing agents as apoptotic responses induced by TNF and cyclohexamide were not altered after CO treatment (data not shown). Further evidence of the effects of CO on PC3 cells in the presence of camptothecin showed that compared to air controls, CO induced significantly stronger cleavage of caspase 3, augmented DNA damage as measured by comet assay, and induced Gadd45α expression, an important regulator of apoptosis and DNA repair that is induced in response to chemotherapy (Supplementary Fig 1 D-F and Supplementary Fig 2) .
Many reports detail the protective effects afforded by CO and HO-1 in response to oxidative stress in primary cells (33) (34) (35) , which is in contrast to the above effects in prostate cancer cells. Treatment of normal prostate epithelial cells (PNT1A) with doxorubicin showed that unlike prostate cancer cells, CO prevented doxorubicin-induced death of normal prostate cells (Fig 2F and Supplementary Fig 1G) supporting the remarkable selectivity of HO-1 and CO to enhance killing of tumor cells while protecting primary cells. We confirmed these findings using primary mouse embryonic fibroblasts (MEF) treated with camptothecin or doxorubicin at the highest doses used in cancer cells and evaluated the effects of CO. As expected we observed 75-90% cell death in response to both chemotherapeutics in air-treated cells. Similar to PNT1A, CO protected primary mouse embryonic fibroblasts (MEF) against doxorubicin-induced cell death versus air-treated cells (Supplementary Fig 1H) . The protection of primary cells afforded by CO is independent of p53, a well-characterized modulator of cell death in response to DNA damage. CO was also able to protect p53 -/-MEF ( Supplementary   Fig 1H) .
Carbon monoxide inhibits growth of human prostate cancer xenografts. 
CAN-13-1075
We next evaluated the role of CO alone and CO in combination with doxorubicin on the growth of tumors in vivo, employing PC3 human prostate cancer xenografts implanted subcutaneously in nude mice. Mice with established tumors were exposed to a regimen of CO (250 ppm for one hr once/day at the same time of day) ± doxorubicin (doxorubicin was injected immediately after CO treatment) and growth was monitored over 2 weeks at which point volumes of tumors were measured and harvested for histological analyses. Mice treated with CO or doxorubicin alone showed significant tumor growth arrest versus controls as measured by tumor volume and Ki67 expression and had no effect on body weight (Fig 3A and   Supplementary Fig 3A-B) . Combination treatment with doxorubicin plus CO showed further additive effects with regard to tumor size, proliferative index and neovascularization (Fig 3B-F) . We did, however, observe a significant effect of CO alone or in combination with doxorubicin on cell death that was not observed with doxorubicin alone suggesting a distinct cellular target for CO (Fig 3G-H) . Mitotic catastrophe as assessed by occurrence of aberrant nuclei after cell division was present among the P-Histone H3 positive cells in tumors treated with CO or doxorubicin (insets in Fig 3E) . Validation of the effects of CO with immunostaining showed that CO inhibited the cell cycle marker cyclin A2 (densitometric analyses: Air+Dox: 1.15±0.28, CO+Dox: 0.68±0.09, p<0.05; Supplementary Fig 4A-B) . The number of Thy positive fibroblasts was markedly decreased in animals receiving CO versus Air treatment. It was not determined whether this was due to less infiltration or increased cell death (Supplementary Fig 4C) . Depletion of Thy-1 positive stromal cells may be an additional early 
Carbon monoxide induces apoptosis and blocks mitosis and angiogenesis in a model of orthotopic prostate cancer in mice.
In a more clinically relevant model of orthotopic PC3 prostate cancer tumors, CO suppressed the mitotic index as measured by P-Histone H3 and CD31 staining in established tumors (8% and 6% respectively, Fig 4A-C) . Importantly, CO significantly suppressed a key marker of invasion and early metastasis known as urokinase type plasminogen activator (uPA) (Fig 4D) . Further, CO showed the trend towards decreased expression of the tumor markers MMP2 and VEGF, however it did not reach significance (Fig 4D) . Similar to the subcutaneous tumor xenograft model, CO induced greater cell death in orthotopic tumors as compared to tumors from air-treated mice (Fig 4E-F; 35% in CO versus 15% in Air) suggesting that in addition to arresting growth, CO reduced the invasive and aggressive phenotype with a signature of mitochondrial collapse and tissue necrosis. This was different then that observed in vitro where CO alone did not affect cancer cell death yet inhibited cell cycle. In both tumor models, we observed a significant increase in the amount of CO present within the tumor tissue as well as in the liver and lung of CO-exposed mice (Fig 4G and data not shown) .
Carbon monoxide prevents development of PIN/carcinoma lesions in TRAMP mice and inhibits lung carcinoma growth in Kras4bG12D transgenic mice
CO was tested in two additional models of spontaneously developed tumors using the prostate tumor TRAMP and the lung tumor Kras mouse models(36, 37). We started CO multiple PIN foci and adenocarcinoma (Fig 5A-B) . In contrast, CO-treated mice had fewer PIN foci and significantly less Ki-67 positive cells and some of the CO-treated TRAMP mice were completely lesion-free (Fig 5A-B) . Importantly, during the progression of the disease and in contrast to the normal prostate where HO-1 is localized to the cytoplasm, HO-1 was expressed in the nucleus in the PIN lesions (Fig 5C) . Staining for the mitochondrial stress response marker mtTFA showed a significant increase in the number of mitochondria in the lesions of COtreated TRAMP mice as compared to the neoplastic lesions in Air-treated TRAMP mice at the same age (Fig 5D) .
A similar effect on tumor growth was observed in the Kras lung tumor model where we observed a significant inhibition in both the frequency (average, n=24 in Air vs n=15 in CO) as well as the size of the tumor nodules in the lung in animals treated with CO versus Air (Fig 5E) .
Proliferation of tumors was also significantly inhibited as evidenced by decreased Ki67 staining ( Figure 5F ). Longer treatment with CO resulted in further inhibition of tumor growth and size of the nodules (data not shown).
Carbon monoxide targets mitochondria to induce death of cancer cells
We next explored potential molecular mechanisms by which CO exerted its effects using prostate cancer cells as our model. Of note, HO-1 and CO have been shown to induce growth arrest of human cancer cells (38) as well as murine AC29 mesothelioma cells (55% less cells at day 2 and 80% at day 5 vs air controls) which support a more global effect of CO in different type of cancer cells. Given that CO is known to target mitochondria, and the data presented in exposure which was accompanied by reactive oxygen species (ROS) generation in PC3 cells that correlated with decreased extracellular acidification rates (ECAR) and lactate levels (Fig   6A-E) . Use of the mitochondrial complex I poison rotenone to compare CO to another mitochondrial targeting compound and whether it would have similar effects in these cells as CO, showed complete blockage of the OCR as was expected with rotenone and this effect occurred in both cancer and non-cancer cells (Fig 6B) . We also tested mitochondrial potential using the JC-1 dye. As previously reported in other cell types(39) CO increased mitochondria membrane potential in PC3 cells (Supplementary Fig 5) . CO did inhibit OCR in normal cells, again suggesting a selective difference in the response of cancer cells and normal PNT1A cells to CO (Fig 6B) . The activation of mitochondrial activity by CO is likely contributes to a less cancerous phenotype. As the treatment time with CO was extended, PC3 cells showed clear G1 arrest (Fig 6F) , which corresponded to significant inhibition of metabolic activity of cancer cells as measured by SPECT (Fig 6G) . Further, exposure to CO induced mitochondrial stress as evidenced by increased mtTFA, cytochrome C positive staining and an inhibition in the oxidized state of mitochondria (Fig 6H-K) . Metabolic screening showed that exposure of PC3 cells to CO for 6h resulted in a decrease in glucose metabolism and influenced synthetic pathways involved in nucleotide and amino acid synthesis all of which corroborate the effects of CO on cancer cell growth ( Table 1, Supplementary Table S1 and Supplementary Fig 6) .
In efforts to further investigate the role of mitochondria in the effects observed with CO, we depleted mitochondria from cancer cells (Rho o cells), which resulted in epithelial to mesenchymal transition as evident by the emergence of fibroblast-like shaped cells and enhanced expression of vimentin in the Rho o cells compared to control which was unaffected by CO further suggestive of mitochondrial targeting by CO (Fig 6L) . Figure 7) .
Discussion
In the present study, we elucidate a role for carbon monoxide in modulation of prostate and lung tumor growth and survival. CO not only mimics the effects of chemotherapy alone by blocking proliferation, but also amplifies tumor cell death when treated in combination with either doxorubicin or camptothecin. Further, we provide evidence that CO reduces the tumor burden in xenograft and transgenic mouse models of prostate and lung cancers and effectively blocks progression of neoplasia and adenocarcinoma. We deduce that CO effectively switches the metabolic state of the cancer cell to fuel oxidative metabolism and decreases in nucleotide and amino acid synthetic pathways. Collectively this causes cell cycle arrest and collapse under intense mitochondrial-dependent oxidative stress. In vitro, this elicits a 1000 fold increase in sensitivity to genotoxins fostered in part by a mitochondria-dependent increase in reactive oxygen species (ROS) generation. In vivo, the role of CO and ROS on tumor growth is less clear and likely involves other cellular mechanisms including hypoxia and perhaps a heightened CAN-13-1075 immune response. Importantly, CO protects normal cells from DNA damage by cytotoxic agents in part by reducing oxygen consumption and eliciting a hibernation-like state that has been observed in other cell types such as T cells and smooth muscle cells with the induction of DNA repair complexes (40) .
HO-1 is an accepted cytoprotective gene in most stress-related pathologies acting to reestablish homeostasis (41, 42) . Others and we have shown that nuclear localized HO-1 no longer possesses enzymatic activity and as such becomes highly associated with cancer and tumor growth (29, 43) . We demonstrate that CO can mimic the effects of enzymatically active HO-1 and that exposure to CO or reinstating HO-1 activity results in enhanced sensitization and acceleration of apoptosis of cancer cells and tumors while protecting normal cells against chemotherapeutic toxicity. This is consistent with prior observations that HO-1-derived CO is important in DNA repair in normal cells (31) . We posit that the subsequent decrease in endogenous CO generation when HO-1 is in the nucleus results in accelerated DNA stress and damage and thus serves as a hallmark of early carcinogenesis.
In our cohort of patients, nuclear HO-1 is increased in a subset of PCa patients with a shorter time to BCR. We did not observe a significant association of HO-1 expression with Gleason grades due to the relatively low number of cohort cases with the most advanced disease invasion of breast cancer cells (13) as well as lung adenocarcinoma cells (38) . The effects of HO-1 on tumor growth and progression is complex and likely depends on cancer types, the cell cycle status, the model system, as well as the methods of pharmacologic or genetic manipulation of HO-1 activity.
In our model of human tumor xenografts in vivo, we observed strong inhibition of angiogenic markers, mitosis and accelerated apoptosis in tumors treated with CO. Further, CO sensitized cancer cells and solid tumors to apoptosis with apparent mitotic catastrophe likely influenced by cellular exhaustion as evidenced by our biochemical data (Figure 6 ). The effects of CO on mitochondria have been well described and we speculate that the high metabolic requirements of cancer cells lends itself to greater effects of CO on survival given that CO is known to target mitochondrial respiratory complexes (32) . This is supported by the effects of CO on mitochondrial membrane potential (46) , biogenesis (35) , and decreased prohibitin (data not shown), which regulate cancer cell survival and growth. PC-3 xenografts are partially resistant to doxorubicin induced apoptosis which delays tumor growth through mitotic blockade (47) . In summary, we demonstrate that HO-1 expression in cancer specimens is targeted to the nucleus in moderately differentiated tumor cells for reasons that remain to be elucidated.
Collectively, CO influences cellular bioenergetics that we find differs between cancer cells and normal cells. CO accelerates oxidative metabolism and ROS generation, unlike in non-cancer cells where CO inhibits respiration and protects against cell death. Insufficient respiration due to dysfunctional mitochondria drives what is known as the Warburg effect. Exposure to CO employs Warburg physiology as an advantage; compelling the cancer cell to consume more oxygen that in turn drives metabolic demand leading to growth inhibition, cellular exhaustion and death. These data provide the first evidence demonstrating the potential for safe, low amounts of CO to be used as an adjuvant therapeutic option for the treatment of cancer. One might envision a specific inhalational therapy regimen being implemented such as that used here to treat cancer patients with inhaled CO using a specific metered dosing delivery device or a CO releasing molecule (CO-RM) (50 
